Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Both the tumor and tumor microenvironment (TME) are crucial for pathogenesis and chemotherapy resistance in multiple myeloma (MM). Bortezomib, commonly used for MM treatment, works on both MM and TME cells, but innate and acquired resistance easily develop. By single-cell RNA sequencing (scRNA-seq), we investigated bone marrow aspirates of 18 treatment-naïve MM patients who later received bortezomib-based treatments. Twelve plasma and TME cell types and their subsets were identified. Suboptimal responders (SORs) to bortezomib exhibited higher copy number alteration burdens than optimal responders (ORs). Forty-four differentially expressed genes for SORs based on scRNA-seq data were further analyzed in an independent cohort of 90 treatment-naïve MMs, where 24 genes were validated. A combined model of three clinical variables (older age, low absolute lymphocyte count, and no autologous stem cell transplantation) and 24 genes was associated with bortezomib responsiveness and poor prognosis. In T cells, cytotoxic memory, proliferating, and dysfunctional subsets were significantly enriched in SORs. Moreover, we identified three monocyte subsets associated with bortezomib responsiveness and an MM-specific NK cell trajectory that ended with an MM-specific subset. scRNA-seq predicted the interaction of the GAS6-MERTK, ALCAM-CD6, and BAG6-NCR gene networks. Of note, tumor cells from ORs and SORs were the most prominent sources of ALCAM on effector T cells and BAG6 on NK cells, respectively. Our results indicate that the complicated compositional and molecular changes of both tumor and immune cells in the bone marrow (BM) milieu are important in the development and acquisition of resistance to bortezomib-based treatment of MM.
Abstract
Both the tumor and tumor microenvironment (TME) are crucial for pathogenesis and chemotherapy resistance in multiple myeloma (MM). Bortezomib, commonly used for MM treatment, works on both MM and TME cells, but innate and acquired resistance easily develop. By single-cell RNA sequencing (scRNA-seq), we investigated bone marrow aspirates of 18 treatment-naïve MM patients who later received bortezomib-based treatments. Twelve plasma and TME cell types and their subsets were identified. Suboptimal responders (SORs) to bortezomib exhibited higher copy number alteration burdens than optimal responders (ORs). Forty-four differentially expressed genes for SORs based on scRNA-seq data were further analyzed in an independent cohort of 90 treatment-naïve MMs, where 24 genes were validated. A combined model of three clinical variables (older age, low absolute lymphocyte count, and no autologous stem cell transplantation) and 24 genes was associated with bortezomib responsiveness and poor prognosis. In T cells, cytotoxic memory, proliferating, and dysfunctional subsets were significantly enriched in SORs. Moreover, we identified three monocyte subsets associated with bortezomib responsiveness and an MM-specific NK cell trajectory that ended with an MM-specific subset. scRNA-seq predicted the interaction of the GAS6-MERTK, ALCAM-CD6, and BAG6-NCR gene networks. Of note, tumor cells from ORs and SORs were the most prominent sources of ALCAM on effector T cells and BAG6 on NK cells, respectively. Our results indicate that the complicated compositional and molecular changes of both tumor and immune cells in the bone marrow (BM) milieu are important in the development and acquisition of resistance to bortezomib-based treatment of MM.
참고문헌 (50)
- Kyle, R. A., "Multiple myeloma", N. Engl. J. Med, 351, pp.1860~1873 (2004)
- Nooka, A. K., "Treatment options for relapsed and refractory multiple myeloma", Blood, 125, pp.3085~3099 (2015)
- Voorhees, P. M., "Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial", Blood, 136, pp.936~945 (2020)
- Kumar, S., "Efficacy of venetoclax as targeted therapy for relapsed", refractory t(11;14)multiple myeloma, 2017, pp.130, 2401~2409
- Pawlyn, C., "Toward personalized treatment in multiple myeloma based on molecular characteristics", Blood, 133, pp.660~675 (2019)
- Kane, R. C., "Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy", Oncologist, 8, pp.508~513 (2003)
- Rajkumar, S. V., "Multiple myeloma : 2020 update on diagnosis, risk-stratification and management", Am. J. Hematol, 95, pp.548~567 (2020)
- Pantani, L., "Bortezomib and dexamethasone as salvage therapy in patients with relapsed", refractory multiple myeloma : analysis of long-term clinical outcomes, 2014, pp.93, 123~128
- Ubels, J., "Gene networks constructed through simulated treatment learning can predict proteasome inhibitor benefit in multiple myeloma", Clin. Cancer Res, 26, pp.5952~5961 (2020)
- Jimenez-Sanchez, "Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient", Cell, 170, pp.927~938.e920 (2017)
- Luca, B. A., "Atlas of clinically distinct cell states and ecosystems across human solid tumors", Cell, 184, pp.5482~5496.e5428 (2021)
- Lo, C. S., "Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy", Clin. Cancer Res, 23, pp.925~934 (2017)
- Jiang, Y., "Tumor immune microenvironment and chemosensitivity signature for predicting response to chemotherapy in gastric cancer", Cancer Immunol. Res, 7, pp.2065~2073 (2019)
- Fairfield, H., "Multiple myeloma in the marrow : pathogenesis and treatments", Ann. N. Y. Acad. Sci, 1364, pp.32~51 (2016)
- Gulla, A., "Bortezomib induces anti-multiple myeloma immune response mediated by cGAS", STING pathway activation, 2021, pp.2, 468~483
- Suva, M. L., "Single-cell RNA sequencing in cancer: lessons learned and emerging challenges", Mol. Cell, 75, pp.7~12 (2019)
- Baslan, T., "Unravelling biology and shifting paradigms in cancer with single-cell sequencing", Nat. Rev. Cancer, 17, pp.557~569 (2017)
- Azizi, E., "Single-cell map of diverse immune phenotypes in the breast tumor microenvironment", Cell, 174, pp.1293~1308.e1236 (2018)
- Ledergor, G., "Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma", Nat. Med, 24, pp.1867~1876 (2018)
- Ryu, D., "Alterations in the Transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion", Clin. Cancer Res, 26, pp.935~944 (2020)
- Zavidij, O., "Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma", Nat. Cancer, 1, pp.493~506 (2020)
- Cohen, Y. C., "Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing", Nat. Med, 27, pp.491~503 (2021)
- Liu, R., "Co-evolution of tumor and immune cells during progression of multiple myeloma", Nat. Commun, 12, pp.2559~ (2021)
- Oetjen, K. A., "Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry", JCI Insight, 3, pp.e124928~ (2018)
- Pavlasova, G., "The regulation and function of CD20 : an"enigma"of B-cell biology and targeted therapy", Haematologica, 105, pp.1494~1506 (2020)
- van der Leun, A. M., "CD8(+)T cell states in human cancer : insights from single-cell analysis", Nat. Rev. Cancer, 20, pp.218~232 (2020)
- Yang, C., "Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome", Nat. Commun, 10, pp.3931~ (2019)
- Jin, S., "Inference and analysis of cell–cell communication using CellChat", Nat. Commun, 12, pp.1088~ (2021)
- Zang, M., "Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s", Oncogenesis, 9, pp.31~ (2020)
- Arbab, A., "Plasma cell dedifferentiation in refractory multiple myeloma", Br. J. Haematol, 193, pp.212~ (2021)
- Stessman, H. A., "Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma", PLoS ONE, 8, pp.e77608~ (2013)
- Avet-Loiseau, H., "Genetic abnormalities and survival in multiple myeloma : the experience of the Intergroupe Francophone du Myelome", Blood, 109, pp.3489~3495 (2007)
- Sewify, E. M., "Cyclin D1amplification in multiple myeloma is associated with multidrug resistance expression", Clin. Lymphoma Myeloma Leuk, 14, pp.215~222 (2014)
- Barrena, S., "Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation", Leukemia, 19, pp.1376~1383 (2005)
- Fan, F., "The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment", Leukemia, 31, pp.1570~1581 (2017)
- Vallet, S., "A novel role for CCL3(MIP-1alpha)in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function", Leukemia, 25, pp.1174~1181 (2011)
- Zhang, L., "Role of RACK1 on cell proliferation, adhesion, and bortezomib-induced apoptosis in multiple myeloma", Int. J. Biol. Macromol, 121, pp.1077~1085 (2019)
- Li, M., "Combined inhibition of Notch signaling and Bcl-2", Bcl-xL results in synergistic antimyeloma effect, 2010, pp.9, 3200~3209
- Zhang, X., "Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression", BMC Cancer, 18, pp.551~ (2018)
- Chapman, M. A., "RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib", lenalidomide decision signature, 2018, pp.132, 2154~2165
- Galletti, G., "Two subsets of stem-like CD8(+)memory T cell progenitors with distinct fate commitments in humans", Nat. Immunol, 21, pp.1552~1562 (2020)
- Zheng, L., "Pan-cancer single-cell landscape of tumor-infiltrating T cells", Science, 374, pp.abe6474~ (2021)
- Dalva-Aydemir, S., "Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin", Clin. Cancer Res, 21, pp.1161~1171 (2015)
- Kirane, A., "Warfarin blocks Gas6-mediated axl activation required for pancreatic cancer epithelial plasticity and metastasis", Cancer Res, 75, pp.3699~3705 (2015)
- Waizenegger, J. S., "Role of growth arrest-specific gene 6-Mer axis in multiple myeloma", Leukemia, 29, pp.696~704 (2015)
- Zimmerman, A. W., "Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells", Blood, 107, pp.3212~3220 (2006)
- Barrow, A. D., "The natural cytotoxicity receptors in health and disease", Front. Immunol, 10, pp.909~ (2019)
- Binici, J., "A soluble fragment of the tumor antigen BCL2-associated athanogene 6(BAG-6)is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells", J. Biol. Chem, 288, pp.34295~34303 (2013)
- Shi, C., "Monocyte recruitment during infection and inflammation", Nat. Rev. Immunol, 11, pp.762~774 (2011)
- Zeissig, M. N., "Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo", Haematologica, 106, pp.3176~3187 (2021)